- Home
- ZYME vs NAVI Comparison
ZYME vs NAVI Comparison
Compare ZYME & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- NAVI
- Stock Information
- Founded
- ZYME 2003
- NAVI 1973
- Country
- ZYME United States
- NAVI United States
- Employees
- ZYME N/A
- NAVI N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- ZYME Health Care
- NAVI Finance
- Exchange
- ZYME Nasdaq
- NAVI Nasdaq
- Market Cap
- ZYME 1.2B
- NAVI 1.3B
- IPO Year
- ZYME 2017
- NAVI N/A
- Fundamental
- Price
- ZYME $16.46
- NAVI $11.72
- Analyst Decision
- ZYME Strong Buy
- NAVI Hold
- Analyst Count
- ZYME 7
- NAVI 7
- Target Price
- ZYME $22.00
- NAVI $14.14
- AVG Volume (30 Days)
- ZYME 889.7K
- NAVI 672.1K
- Earning Date
- ZYME 11-06-2025
- NAVI 10-29-2025
- Dividend Yield
- ZYME N/A
- NAVI 5.48%
- EPS Growth
- ZYME N/A
- NAVI N/A
- EPS
- ZYME N/A
- NAVI N/A
- Revenue
- ZYME $134,481,000.00
- NAVI $443,000,000.00
- Revenue This Year
- ZYME $99.52
- NAVI N/A
- Revenue Next Year
- ZYME N/A
- NAVI $1.57
- P/E Ratio
- ZYME N/A
- NAVI N/A
- Revenue Growth
- ZYME 116.21
- NAVI N/A
- 52 Week Low
- ZYME $9.03
- NAVI $10.53
- 52 Week High
- ZYME $19.98
- NAVI $16.07
- Technical
- Relative Strength Index (RSI)
- ZYME 36.30
- NAVI 36.25
- Support Level
- ZYME $17.27
- NAVI $11.47
- Resistance Level
- ZYME $19.98
- NAVI $12.27
- Average True Range (ATR)
- ZYME 0.76
- NAVI 0.36
- MACD
- ZYME -0.27
- NAVI -0.06
- Stochastic Oscillator
- ZYME 11.48
- NAVI 11.42
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.